Drugs / 68Ga-RM26-RGD
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05549024 | Aug 2022 → Dec 2025 overdue | brain neoplasm, breast cancer, prostate cancer | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-RM26-RGD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05549024 ↗ |
| Modality | Diagnostic / imaging agent | “novel dual-target imaging agent 68Ga-RM26-RGD was used for PET/CT imaging” NCT05549024 ↗ |
| Route | Intravenous | “Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.” NCT05549024 ↗ |